Search Results

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , will present a poster this week at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting . The conference will be held online as a virtual event. Cygnal’s poster will discuss research on t

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, will present two posters at the American Association for Cancer Research (AACR) Annual Meeting 2021, which will take place virtually from April 10-15 and May 17-21, 2021.

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, today announced that Pearl Huang, Ph.D., President and Chief Executive Officer, will present a company overview at the 2020 Stifel Virtual Healthcare Conference on Tuesday, November 17, 2020 at 8:40 a.m. E.T.

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, announced that it has been named as one of Chemical & Engineering News’ 10 Start-Ups to Watch in 2020.

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , today announced that Pearl Huang, Ph.D., President and Chief Executive Officer, will present a company overview at the Piper Sandler 32nd Annual Virtual Healthcare Conference. The presentation will be available fo

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, today announced the company’s Scientific Advisory Board (SAB).

Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology , today announced that Pearl Huang, Ph.D., President and Chief Executive Officer, will present a company overview as part of Wells Fargo’s 2020 Virtual Healthcare Conference on Wednesday, September 9, 2020 at 3:

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero Therapeutics is looking to extend its cash runway while it focuses on other assets in its pipeline.